Quinoxalines and AZA-quinoxalines as CRTH

1. A compound of the formula (I)

or a pharmaceutically acceptable salt thereof, wherein

J 1 and J 2 are independently C(H), C(R 1 ), C(R 22 ), or N wherein the following provisos apply

(i) no more than one of J 1 and J 2 is N,

(ii) no more than one of J 1 and J 2 is C(R 22 ); and

(iii) only one R 1 is substituted on the illustrated ring containing J 1 and J 2 ;

R 1 is selected from the group consisting of

(i) —C(O)—N(R 6a )(R 6b ),

(ii) —S(O) 2 —N(R 6a )(R 6b ),

(iii) —C(O)—C(R 7a )(R 7b )(R 7c ),

(iv) —N(H)—C(O)—C(R 7a )(R 7b )(R 7c ),

(v) —C(O)—O—C(R 7a )(R 7b )(R c ), and

(vi) —N(H)—S(O) 2 —C(R 7a )(R 7b )(R 7c );

R 6a and R 6b are independently

a. H,

b. C 1 -C 6 alkyl,

c. C 3 -C 6 alkenyl,

d. C 3 -C 6 alkynyl,

e. —O—(C 1 -C 3 alkyl),

f. -Q-R AH , wherein R AH is phenyl or 5- to 6-membered heteroaryl containing 1 to 2 heteroatoms independently selected from the group consisting of N, O, and S,

and wherein R AH is unsubstituted or substituted with 1 to 5 R 8 moieties independently selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 3 fluoroalkyl, —O—(C 1 -C 3 fluoroalkyl), hydroxyl, phenyl, and —CN;

Q is selected from the group consisting of

(a) a bond;

(b) C 1 -C 6 alkylene, wherein said C 1 -C 6 alkylene is unsubstituted or substituted by 1 to 2 fluoro, C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl, or C 1 -C 3 fluoroalkyl; and

(c)

 wherein t is 1, 2, 3, or 4;

g. -Q-R Hc , wherein R HC is

(i) 5- to 7-membered heterocyclyl containing 1 heteroatom selected from the group consisting of N, O, S, S(O), and S(O) 2 , wherein said heterocyclyl of R HC is optionally fused to a benzene, pyridyl ring; or

(ii) C 3 -C 7 cycloalkyl, wherein said cycloalkyl of R HC is optionally fused to a benzene or pyridyl ring;

and wherein R HC is unsubstituted or substituted with 1 to 5 R 12 moieties independently selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 3 fluoroalkyl,

—O—(C 1 -C 3 fluoroalkyl), hydroxyl, —CN, and —S(O) 2 —(C 1 -C 3 alkyl), or wherein when two R 12 moieties are geminally substituted on the same carbon atom, the two geminally substituted R 12 moieties, together with the carbon atom on which they are attached form —C(O)—;

Q is selected from the group consisting of

(a) a bond;

(b) C 1 -C 6 alkylene, wherein said C 1 -C 6 alkylene is unsubstituted or substituted by 1 to 2 fluoro, C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl, or C 1 -C 3 fluoroalkyl; and

 wherein t is 1, 2, 3, or 4;

h. or R 6a and R 6b together with the N atom to which they are attached form R 6H , wherein R 6H is independently selected from the group consisting of

(i) a 4- to 9-membered heterocyclyl, optionally containing one additional nitrogen atom, wherein said heterocyclyl of R 6H is optionally fused to phenyl, C 3 -C 6 cycloalkyl, or a 5-membered heteroaryl containing 1 to 3 N atoms;

(ii) a 4- to 7-membered heterocyclenyl, optionally containing one additional nitrogen atom, wherein said heterocyclenyl of R 6H is optionally fused to phenyl; and

(iii) a 6- to 8-membered aza- or a diazabicycloheterocycloalkyl ring;

wherein R 6H is unsubstituted or substituted by 1 to 5 R 9 moieties wherein each R 9 moiety is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 3 fluoroalkyl, fluoro, hydroxyl, —CN,

—(C 1 -C 3 alkylene)-(C 1 -C 3 alkoxy), or

R 9 is —Z—R CY wherein

 Z is

 (i) a bond,

 (ii) —C(O)—,

(iii) —C(═N—OH)—,

 (iv) —S(O) 2 —,

 (v) C 1 -C 3 alkylene, wherein said C 1 -C 3 alkylene of Z is optionally substituted by 1 to 2 fluoro or C 1 -C 3 alkyl;

 (vi) —O—;

 (vii) —O—(C 1 -C 3 alkylene)-; or

 (viii) —C(O)—O—CH 2 —

 R CY is selected from the group consisting of

 (i) phenyl

 (ii) 5- to 10-membered mono or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S; or

 (iii) 5- to 6-membered heterocyclyl containing 1 to 2 N atoms or 1 O atom, wherein said heterocyclyl of R CY is optionally fused to phenyl;

 wherein R CY is unsubstituted or substituted by 1 to 4 R H ) moieties;

 each R 10 moiety is independently C 1 -C 3 alkyl, halo, hydroxyl, C 1 -C 3 alkoxy, C 1 -C 3 fluoroalkyl, —(C 1 -C 3 alkylene)-(C 1 -C 3 alkoxy), —S(O) 2 —(C 1 -C 3 alkyl), —C(O)—(C 1 -C 3 alkyl), —CN, pyridyl, or cyclopropyl or, wherein when two R 10 moieties are geminally substituted on a common carbon atom, together with the carbon atom on which they are substituted, form —C(O)—;

or, optionally, where two R 9 moieties are geminally substituted on a common ring carbon of R 6H , the two R 9 moieties, together with the ring carbon on which they are substituted, form R YC , wherein R YC is

 (i) a 4- to 7-membered cycloalkyl, wherein said cycloalkyl of R YC is optionally fused to phenyl or pyridyl; or

 (ii) a 4- to 7-membered heterocyclyl containing 1 to 2 N atoms or 1 O atom, wherein said heterocyclyl of R YC is optionally fused to phenyl;

 wherein R YC is unsubstituted or substituted by 1 to 4 R 11 moieties;

 each R 11 moiety is independently C 1 -C 3 alkyl, halo, hydroxyl, C 1 -C 3 alkoxy, —(C 1 -C 3 alkylene)-(C 1 -C 3 alkoxy), —S(O) 2 —(C 1 -C 3 alkyl), —C(O)—(C 1 -C 3 alkyl), phenyl, or pyridyl, or, wherein when two R 11 moieties are geminally substituted on a common carbon atom, together with the carbon atom on which they are substituted, form —C(O)—;

R 7a and R 7b are independently

a) H,

b) C 1 -C 6 alkyl,

c) R 7a and R 7b together with the carbon atom on which they are substituted, form R PC , wherein R PC is

(i) C 3 -C 7 cycloalkyl, or

(ii) phenyl, wherein said phenyl of R PC is unsubstituted or substituted by 1 to 5 moieties independently selected from the group consisting of halo, trifluoromethyl, and trifluoromethoxy;

R 7c is

a) H, or

b) absent, when R 7a and R 7b together with the carbon atom on which they are substituted form phenyl;

R 22 is halo, C 1 -C 3 alkyl, or C 1 -C 3 fluoroalkyl;

b is 0 or 1;

X is a bond, —O—, —S—, —S(O)—, —S(O) 2 —, or N(H);

Y is selected from the group consisting of

(i) a bond,

 (iv) —O—, (v) —S—, (vi) —S(O)—, and

(vii) —S(O) 2 —;

wherein

a is 0, 1, 2, or 3;

r is 0, 1, or 2;

s is 0, 1, or 2;

each occurrence of R 4 is independently halo, C 1 -C 6 alkyl, or C 1 -C 6 fluoroalkyl;

R a , R b , R c , and R d are independently H, fluoro, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, or C 1 -C 6 alkoxy;

R 2 is selected from the group consisting of

(i) phenyl; and

(ii) 5- to 6-membered heteroaryl containing from 1 to 3 heteroatoms selected from the group consisting of N, O, and S;

wherein R 2 is unsubstituted or substituted by 1 to 5 R 5 groups independently selected from the group consisting of halo, C 1 -C 3 fluoroalkyl, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, —CN, —OCF 3 , —C(O)—(C 1 -C 3 alkyl), and —S(O) 2 —(C 1 -C 3 alkyl);

R 3 is —C(O)OH,

 or —N(H)—SO 2 —R e ,

wherein R e is C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 alkoxy, and phenyl;

n is 1, 2, 3, 4, or 5; and

q is 0, 1, or 2.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of:

(i) —C(O)—N(R 6a )(R 6b ),

(ii) —S(O) 2 —N(R 6a )(R 6b ),

(iii) —C(O)—C(R 7a )(R 7b )(R 7c ),

(iv) —N(H)—C(O)—C(R 7a )(R 7b )(R 7c ),

(v) —C(O)—O—C(R 7a )(R 7b )(R 7c ), and

(vi) —N(H)—S(O) 2 —C(R 7a )(R 7b )(R 7c );

R 6a and R 6b are independently:

a. H,

b. C 1 -C 6 alkyl,

c. C 3 -C 6 alkenyl,

d. C 3 -C 6 alkynyl,

e. —O—(C 1 -C 3 alkyl),

f. -Q-R AH , wherein R AH is phenyl or 5- to 6-membered heteroaryl containing 1 to 2 heteroatoms independently selected from the group consisting of N, O, and S,

and wherein R AH is unsubstituted or substituted with 1 to 5 R 8 moieties independently selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 3 fluoroalkyl, —O—(C 1 -C 3 fluoroalkyl), hydroxyl, phenyl, and —CN;

Q is selected from the group consisting of

(a) a bond;

(b) C 1 -C 6 alkylene, wherein said C 1 -C 6 alkylene is unsubstituted or substituted by 1 to 2 fluoro, C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl, or C 1 -C 3 fluoroalkyl; and

(c)

 wherein t is 1, 2, 3, or 4;

g. -Q-R HC , wherein R HC is

(i) 5- to 6-membered heterocyclyl containing 1 heteroatom selected from the group consisting of N and O, wherein said heterocyclyl of R HC is optionally fused to a benzene ring; or

(ii) C 5 -C 7 cycloalkyl, wherein said cycloalkyl of R HC is optionally fused to a benzene ring;

and wherein R HC is unsubstituted or substituted with 1 to 5 R 12 moieties independently selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, C 1 -C 3 fluoroalkyl,

—O—(C 1 -C 3 fluoroalkyl), hydroxyl, and —CN, or wherein when two R 12 moieties are geminally substituted on the same carbon atom, the two geminally substituted R 12 moieties, together with the carbon atom on which they are attached form —C(O)—;

Q is selected from the group consisting of

(a) a bond;

(b) C 1 -C 6 alkylene, wherein said C 1 -C 6 alkylene is unsubstituted or substituted by 1 to 2 fluoro, C 1 -C 3 alkyl, C 1 -C 3 hydroxyalkyl, or C 1 -C 3 fluoroalkyl; and

(c)

 wherein t is 1, 2, 3, or 4;

h. or R 6a and R 6b together with the N atom to which they are attached form R 6H , wherein R 6H is independently selected from the group consisting of

(i) a 4- to 7-membered heterocyclyl, optionally containing one additional nitrogen atom, wherein said heterocyclyl of R 6H is optionally fused to phenyl; and

(ii) a 4- to 7-membered heterocyclenyl, optionally containing one additional nitrogen atom, wherein said heterocyclenyl of R 6H is optionally fused to phenyl;

wherein R 6H is unsubstituted or substituted by 1 to 5 R 9 moieties wherein each R 9 moiety is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, fluoro, hydroxyl, —CN, —(C 1 -C 3 alkylene)-(C 1 -C 3 alkoxy), or

R 9 is —Z—R CY wherein

 Z is

 (i) a bond,

 (ii) —C(O)—,

 (iii) —C(═N—OH)—,

 (iv) —S(O) 2 —, or

 (v) C 1 -C 3 alkylene, wherein said C 1 -C 3 alkylene of Z is optionally substituted by 1 to 2 fluoro or C 1 -C 3 alkyl;

 R CY is selected from the group consisting of

 (i) phenyl

 (ii) 5- to 10-membered mono or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S; or

 (iii) 5- to 6-membered heterocyclyl containing 1 to 2 N atoms or 1 O atom, wherein said heterocyclyl of R CY is optionally fused to phenyl;

 wherein R CY is unsubstituted or substituted by 1 to 4 R 10 moieties;

 each R 10 moiety is independently C 1 -C 3 alkyl, halo, hydroxyl, C 1 -C 3 alkoxy, —(C 1 -C 3 alkylene)-(C 1 -C 3 alkoxy), —S(O) 2 —(C 1 -C 3 alkyl), —C(O)—(C 1 -C 3 alkyl), —CN, or pyridyl, or, wherein when two R 10 moieties are geminally substituted on a common carbon atom, together with the carbon atom on which they are substituted, form —C(O)—;

or, optionally, where two R 9 moieties are geminally substituted on a common ring carbon of R 6H , the two R 9 moieties, together with the ring carbon on which they are substituted, form R YC , wherein R YC is

 (i) a 4- to 7-membered cycloalkyl, wherein said cycloalkyl of R YC is optionally fused to phenyl; or

 (ii) a 4- to 7-membered heterocyclyl containing 1 to 2 N atoms or 1 O atom, wherein said heterocyclyl of R YC is optionally fused to phenyl;

 wherein R YC is unsubstituted or substituted by 1 to 4 R 11 moieties;

 each R 11 moiety is independently C 1 -C 3 alkyl, halo, hydroxyl, C 1 -C 3 alkoxy, —(C 1 -C 3 alkylene)-(C 1 -C 3 alkoxy), —S(O) 2 —(C 1 -C 3 alkyl), —C(O)—(C 1 -C 3 alkyl), phenyl, or pyridyl, or, wherein when two R 11 moieties are geminally substituted on a common carbon atom, together with the carbon atom on which they are substituted, form —C(O)—;

R 7a and R 7b independently

a) H,

b) C 1 -C 6 alkyl,

c) R 7a and R 7b together with the carbon atom on which they are substituted, form R PC , wherein R PC is

(i) C 3 -C 7 cycloalkyl, or

(ii) phenyl, wherein said phenyl of R PC is unsubstituted or substituted by 1 to 5 moieties independently selected from the group consisting of halo, trifluoromethyl, and trifluoromethoxy;

R 7c is

a) H, or

b) absent, when R 7a and R 7b together with the carbon atom on which they are substituted form phenyl; and

X is a bond, —O—, —S—, —S(O)—, or —S(O) 2 —;

J 1 , J 2 , Y, R a , R b , R c , R d , R 2 , R 3 , R 22 , b, n, and q are as specified in claim 1 .

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is substituted at the 6 or 7 position of the illustrated bicyclic ring of Formula (I).

4. The compound of claim 3 or a pharmaceutically acceptable salt thereof, wherein the compound has the formula (IA)

wherein J 1 and J 2 are independently C(H) or C(R 22 ), or N wherein the following provisos apply

(i) no more than one of J 1 and J 2 is N, and

(ii) no more than one of J 1 and J 2 is C(R 22 ).

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of:

(i) —C(O)—N(R 6a )(R 6b ), and

(ii) —S(O) 2 —N(R 6a )(R 6b ).

6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein

(i) R 6a is H and

R 6b is -Q-R AH or -Q-R HC ; or

(ii) R 6a and R 6b together with the N atom to which they are attached form R 6H .

7. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —C(O)—N(R 6a )(R 6b ).

8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein

R 6a is H and

R 6b is -Q-R AH or -Q-R HC .

9. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein R 6a and R 6b together with the N atom to which they are attached form R 6H .

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of

(i) a bond,

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the group

is selected from the group consisting of

12. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of the Formula (I) has the Formula (IB)

wherein

J 1 is C(H) or N;

R 1 is —C(O)—N(R 6a )(R 6b );

I) R 6a is H and R 6b is:

a) -Q-R AH , wherein R AH is phenyl or pyridyl,

and wherein R AH is unsubstituted or substituted with 1 to 2 R 8 moieties independently selected from the group consisting of halo, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, trifluoromethyl, trifluoromethoxy, and —CN;

Q is selected from the group consisting of

(i) a bond;

(ii)

 wherein R e and R f are independently H, C 1 -C 3 alkyl, or trifluoromethyl;

(iii) C 2 -C 4 alkylene, wherein said C 2 -C 6 alkylene is unsubstituted;

b) -Q-R HC , wherein R HC is

(i) 5- to 6-membered heterocyclyl containing 1 heteroatom selected from the group consisting of N and O; or

(ii) C 5 -C 7 cycloalkyl, wherein said C 5 -C 7 cycloalkyl is optionally fused to a benzene ring;

and wherein R HC is unsubstituted or substituted with 1 to 2 R 12 moieties independently selected from the group consisting of C 1 -C 3 alkyl, halo, and hydroxyl, or wherein when two R 12 moieties are geminally substituted on the same carbon atom, the two geminally substituted R 12 moieties, together with the carbon atom on which they are attached form —C(O)—;

II) or R 6a and R 6b together with the N atom to which they are attached form R 6H , wherein R 6H is independently selected from the group consisting of

a) a 4- to 6-membered heterocyclyl, optionally containing one additional nitrogen atom, wherein said 4- to 6-membered heterocyclyl is optionally fused to phenyl; and

b) a 5- to 6-membered heterocyclenyl, optionally containing one additional nitrogen atom, wherein said 4- to 6-membered heterocyclyl is optionally fused to phenyl;

wherein R 6H is unsubstituted or substituted by 1 to 2 R 9 moieties wherein each R 9 moiety is independently C 1 -C 3 alkyl, F, Cl,

 —CN, or

 R 9 is —Z—R CY , wherein

 Z is a bond or —CH 2 —;

 R CY is selected from the group consisting of

 (i) phenyl;

 (ii) 5- to 6-membered heteroaryl containing 1 to 3 N atoms; or

 (iii) 5- to 6-membered heterocyclyl containing 2 N atoms, wherein said 5- to 6-membered heterocyclyl of R CY is fused to phenyl;

 wherein R CY is unsubstituted or substituted by 1 to 2 R 10 moieties;

 each R 10 moiety is independently C 1 -C 3 alkyl, halo, C 1 -C 3 alkoxy, —(C 1 -C 3 alkylene)-(C 1 -C 3 alkoxy), or —CN, or, wherein two R 10 moieties are geminally substituted on a common carbon atom, together with the carbon atom on which they are substituted, form —C(O)—;

 or, optionally, where two R 9 moieties are geminally substituted on a common ring carbon of R 6H , the two R 9 moieties, together with the ring carbon on which they are substituted, form R YC , wherein R YC is

 (i) a 5- to 6-membered cycloalkyl, wherein said or 5- to 6-membered cycloalkyl is fused to phenyl; or

 (ii) a 4- to 6-membered heterocyclyl containing 1 to 2 N atoms or 1 O atom, wherein said or 4- to 6-membered heterocyclyl is optionally fused to phenyl;

 wherein R YC is unsubstituted or substituted by 1 to 3 R H moieties;

 each R 11 moiety is independently C 1 -C 3 alkyl, —C(O)—(C 1 -C 3 alkyl), or phenyl, or, wherein two R 11 moieties are geminally substituted on a common carbon atom, together with the carbon atom on which they are substituted, form —C(O)—;

Y is selected from the group consisting of

(i) a bond,

R c is H or methyl;

R d is H;

R 2 is phenyl, pyridyl, or thienyl;

wherein R 2 is unsubstituted or substituted by 1 to 2 R 5 groups independently selected from the group consisting of fluoro, chloro, trifluoromethyl, C 1 -C 3 alkoxy, —CN, and —OCF 3 ; and

q is 0, 1, or 2.

13. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound of the Formula (I) has the Formula (IC)

wherein

R 1 is —C(O)—N(R 6a )(R 6b );

I) R 6a is H and R 6b is:

a) -Q-R AH , wherein R AH is phenyl,

and wherein R AH is unsubstituted or substituted with one R 8 moiety selected from the group consisting of halo and —CN;

Q is selected from the group consisting of

(i) a bond;

(ii)

 wherein R e is H, and R f is H or methyl;

b) -Q-R HC , wherein R HC is C 5 -C 6 cycloalkyl, wherein said C 5 -C 6 cycloalkyl is fused to a benzene ring;

and wherein R HC is unsubstituted or substituted with 1 to 2 R 12 moieties independently selected from the group consisting of halo and —CN;

II) or R 6a and R 6b together with the N atom to which they are attached form R 6H , wherein R 6H is azetidinyl, pyrrolidinyl, piperidinyl, or piperazinyl;

wherein R 6H is substituted with —Z—R CY , wherein

Z is a bond; and

R CY is unsubstituted phenyl or phenyl substituted by 1 to 2 R 10 moieties selected from the group consisting of halo and —CN;

R 6H is optionally substituted by 1 to 2 R 9 moieties, wherein each R 9 moiety is independently C 1 -C 3 alkyl, halo or —CN, and

R 2 is unsubstituted or substituted by 1 to 2 R 5 groups independently selected from the group consisting of fluoro, chloro, C 1 -C 3 alkyl, trifluoromethyl, C 1 -C 3 alkoxy, —CN, and —OCF 3 .

14. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of

5-(3-phenyl-7-{[4-(trifluoromethyl)benzyl]carbamoyl}pyrido[2,3-b]pyrazin-2-yl)pentanoic acid,

5-{7-[(4-chlorobenzyl)carbamoyl]-3-phenylpyrido[2,3-b]pyrazin-2-yl}pentanoic acid,

5-{3-phenyl-7-[(4-phenylpiperazin-1-yl)carbonyl]pyrido[2,3-b]pyrazin-2-yl}pentanoic acid,

5-(3-phenyl-7-{[(1R)-1-phenylethyl]carbamoyl}quinoxalin-2-yl)pentanoic acid,

5-(3-phenyl-7-{[(1S)-1-phenylethyl]carbamoyl}quinoxalin-2-yl)pentanoic acid,

5-(3-phenyl-7-{[4-(trifluoromethyl)benzyl]carbamoyl}quinoxalin-2-yl)pentanoic acid,

5-(7-{[(1R)-1-(4-fluorophenyl)ethyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(7-{[(1S)-1-(4-fluorophenyl)ethyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-{7-[(3-benzylpiperazin-1-yl)carbonyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-(7-{[3-(4-methoxyphenyl)pyrrolidin-1-yl]carbonyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(7-{[3-(3-chlorophenyl)pyrrolidin-1-yl]carbonyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(3-phenyl-7-{[2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]carbamoyl}quinoxalin-2-yl)pentanoic acid,

5-{7-[(3-benzylpyrrolidin-1-yl)carbonyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-(7-{[3-(4-fluorophenyl)pyrrolidin-1-yl]carbonyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-{7-[(4-chlorobenzyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-{7-[(1-methyl-1-phenylethyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-[7-(benzylcarbamoyl)-3-phenylquinoxalin-2-yl]pentanoic acid,

5-{7-[(2-fluorobenzyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-{7-[(3-fluorobenzyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-{7-[(4-fluorobenzyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-{3-phenyl-7-[(pyridin-2-ylmethyl)carbamoyl]quinoxalin-2-yl}pentanoic acid,

5-{3-phenyl-7-[(4-phenylpiperidin-1-yl)carbonyl]quinoxalin-2-yl}pentanoic acid,

5-{3-phenyl-7-[(2-phenylpiperidin-1-yl)carbonyl]quinoxalin-2-yl}pentanoic acid,

5-{3-phenyl-7-[(3-phenylpyrrolidin-1-yl)carbonyl]quinoxalin-2-yl}pentanoic acid,

5-{3-phenyl-7-[(2-phenylpyrrolidin-1-yl)carbonyl]quinoxalin-2-yl}pentanoic acid,

5-{3-phenyl-7-[(4-phenylpiperazin-1-yl)carbonyl]quinoxalin-2-yl}pentanoic acid,

5-{7-[benzyl(methyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-[7-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)-3-phenylquinoxalin-2-yl]pentanoic acid,

5-[3-phenyl-7-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)quinoxalin-2-yl]pentanoic acid,

5-(7-{[(1-(4-methoxyphenyl)ethyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(3-phenyl-7-{[4-(trifluoromethoxy)benzyl]carbamoyl}quinoxalin-2-yl)pentanoic acid,

5-{7-[(4-methylbenzyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-(7-{[(1R)-1-(4-chlorophenyl)ethyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(7-{[(1R)-1-(4-methylphenyl)ethyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-{7-[(4-ethylbenzyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-{7-[(4-methoxybenzyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-{7-[(4-cyanobenzyl)carbamoyl]-3-phenylquinoxalin-2-yl}pentanoic acid,

5-(7-{[(1S)-1-(4-methylphenyl)ethyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-[3-phenyl-7-({1-[4-(trifluoromethoxy)phenyl]ethyl}carbamoyl)quinoxalin-2-yl]pentanoic acid,

5-[3-phenyl-7-(piperidin-1-ylcarbonyl)quinoxalin-2-yl]pentanoic acid,

5-(7-{[1-(2-fluorophenyl)ethyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-[7-(2,3-dihydro-1H-inden-2-ylcarbamoyl)-3-phenylquinoxalin-2-yl]pentanoic acid,

5-(7-{[(1S)-1-(4-chlorophenyl)ethyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(7-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(7-{[4-(4-methyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl]carbonyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(7-{[4-(5-methyl-1H-1,2,3-triazol-1-yl)piperidin-1-yl]carbonyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-{3-phenyl-7-[(4-pyrazin-2-ylpiperidin-1-yl)carbonyl]quinoxalin-2-yl}pentanoic acid,

5-(7-{[(4-chloropyridin-2-yl)methyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(7-{[(6-chloropyridin-2-yl)methyl]carbamoyl}-3-phenylquinoxalin-2-yl)pentanoic acid,

3-(4-chlorophenyl)-7-[[[(4-chlorophenyl)methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[(3-chlorophenyl)methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[(3-phenyl-1-pyrrolidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[(2,2,2-trifluoro-1(S)-phenylethyl)amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[(4-cyanophenyl)methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[(3 (R)-phenyl-1-pyrrolidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[(3 (R)-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[[4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[1(R)-(4-fluorophenyl)ethyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[1(S)-(4-fluorophenyl)ethyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[1(R)-(4-chlorophenyl)-2,2,2-trifluoroethyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[[3-(trifluoromethoxy)phenyl]methyl]-amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[1(S)-(4-chlorophenyl)ethyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[(4-phenyl-1-piperazinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[(2,2,2-trifluoro-1(R)-phenylethyl)amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[(4-cyano-4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[(4-methylphenyl)methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-beta-methyl-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[1(S)-(4-chlorophenyl)ethyl]amino]carbonyl]-beta-methyl-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-beta-methyl-7-[[[2,2,2-trifluoro-1(S)-phenylethyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

beta-methyl-3-[4-(trifluoromethyl)phenyl]-7-[[(2,2,2-trifluoro-1(S)-phenylethyl)amino]carbonyl]-2-quinoxalinepentanoic acid,

alpha-methyl-7-[(4-phenyl-1-piperidinyl)carbonyl]-3-[4-(trifluoromethyl)phenyl]-2-quinoxalinepentanoic acid,

3-[2-[3-(4-chlorophenyl)-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinyl]ethyl]benzeneacetic acid,

3-[2-[3-(4-chlorophenyl)-7-[[[1(R)-(4-fluorophenyl)ethyl]amino]carbonyl]-2-quinoxalinyl]ethyl]benzeneacetic acid,

2-[2-[3-phenyl-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinyl]ethyl]cyclopropanecarboxylic acid,

6-fluoro-3-phenyl-7-[(3(S)-phenyl-1-pyrrolidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(3-fluorophenyl)-7-[(3-phenyl-1-pyrrolidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(3-chlorophenyl)-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

7-[(4-phenyl-1-piperidinyl)carbonyl]-3-[6-(trifluoromethyl)-3-pyridinyl]-2-quinoxalinepentanoic acid,

3-(2-chlorophenyl)-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

7-[(4-phenyl-1-piperidinyl)carbonyl]-3-[4-(trifluoromethoxy)phenyl]-2-quinoxalinepentanoic acid,

3-(4-methoxyphenyl)-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-cyanophenyl)-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

7-[(4-phenyl-1-piperidinyl)carbonyl]-3-(3-thienyl)-2-quinoxalinepentanoic acid,

3-(2,4-dichlorophenyl)-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

(R)-5-(7-(4-(4-fluorophenyl)-2-methylpiperazine-1-carbonyl)-3-phenylquinoxalin-2-yl)pentanoic acid,

(R)-5-(7-((6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3-phenylquinoxalin-2-yl)pentanoic acid,

(R)-5-(7-(2-methyl-4-phenylpiperazine-1-carbonyl)-3-phenylquinoxalin-2-yl)pentanoic acid,

4-((7-(4-(4-fluorophenyl)piperazine-1-carbonyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid,

(R)-4-((3-phenyl-7-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)quinoxalin-2-yl)amino)butanoic acid,

7-[[[(4-chlorophenyl)methyl]amino]carbonyl]-3-(4-fluorophenyl)-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[[(2,2,2-trifluoro-1(S)-phenylethyl)amino]carbonyl]-2-quinoxalinepentanoic acid,

7-[[(2,3-dihydro-1H-inden-2-yl)amino]carbonyl]-3-(4-fluorophenyl)-2-quinoxalinepentanoic acid,

7-[[[(4-cyanophenyl)methyl]amino]carbonyl]-3-(4-fluorophenyl)-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[(3-phenyl-1-pyrrolidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[[[[4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[[[(4-fluorophenyl)methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[[[1(R)-(4-fluorophenyl)ethyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[[[1(S)-(4-fluorophenyl)ethyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-2-quinoxalinepentanoic acid,

7-[[4-[2,3-dihydro-3-(2-methoxyethyl)-2-oxo-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

7-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

7-[(1,2-dihydro-1-methyl-2-oxospiro[3H-indole-3,4′-piperidin]-1′-yl)carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

3-phenyl-7-(spiro[benzofuran-3(2H),4′-piperidin]-1′-ylcarbonyl)-2-quinoxalinepentanoic acid,

7-[(2,3-dihydrospiro[1H-indene-1,4′-piperidin]-1′-yl)carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

7-[(1,2-dihydro-1-methylspiro[3H-indole-3,4′-piperidin]-1′-yl)carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

7-[(1-acetyl-1,2-dihydrospiro[3H-indole-3,4′-piperidin]-1′-yl)carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

7-[(4-cyano-4-phenyl-1-piperidinyl)carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

7-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)carbonyl]-2-quinoxalinepentanoic acid,

5-(3-(4-fluorophenyl)-7-(4-phenyl-1,2,3,6-tetrahydropyridine-1-carbonyl)quinoxalin-2-yl)pentanoic acid,

7-[(4-cyano-4-phenyl-1-piperidinyl)carbonyl]-3-(4-fluorophenyl)-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[[(phenylmethyl)amino]carbonyl]-2-quinoxalinepentanoic acid,

7-[[[1(R)-(4-chlorophenyl)ethyl]amino]carbonyl]-3-(4-fluorophenyl)-2-quinoxalinepentanoic acid,

7-[[[1(S)-(4-chlorophenyl)ethyl]amino]carbonyl]-3-(4-fluorophenyl)-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[[(1(R)-phenylethyl)amino]carbonyl]-2-quinoxalinepentanoic acid,

7-[[4-(4-chlorophenyl)-1-piperidinyl]carbonyl]-3-(4-fluorophenyl)-2-quinoxalinepentanoic acid,

7-[[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridinyl]carbonyl]-3-(4-fluorophenyl)-2-quinoxalinepentanoic acid,

3-phenyl-7-[(3(S)-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-phenyl-7-[(3(R)-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

5-(7-(4-(1H-imidazol-1-yl)piperidine-1-carbonyl)-3-phenylquinoxalin-2-yl)pentanoic acid,

7-[[[1(R)-(2-pyridinyl)ethyl]amino]carbonyl]-3-[4-(trifluoromethyl)phenyl]-2-quinoxalinepentanoic acid,

7-[(4-phenyl-1-piperidinyl)carbonyl]-3-[4-(trifluoromethyl)phenyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-alpha-methyl-7-[(4-phenyl-1-piperidinyl)carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-alpha-methyl-7-[[(2,2,2-trifluoro-1(S)-phenylethyl)amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[(4-cyanophenyl)methyl]amino]carbonyl]-alpha-methyl-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[1(R)-(4-fluorophenyl)ethyl]amino]carbonyl]-alpha-methyl-2-quinoxalinepentanoic acid,

3-(4-chlorophenyl)-7-[[[1(S)-(4-fluorophenyl)ethyl]amino]carbonyl]-alpha-methyl-2-quinoxalinepentanoic acid,

3-phenyl-7-[(3-phenyl-1-azetidinyl)carbonyl]-2-quinoxalinepentanoic acid,

7-[[3-(4-cyanophenyl)-1-azetidinyl]carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[[(1,2,3,4-tetrahydro-1(R)-naphthalenyl)amino]carbonyl]-2-quinoxalinepentanoic acid,

3-(4-fluorophenyl)-7-[(4-phenyl-1-piperazinyl)carbonyl]-2-quinoxalinepentanoic acid,

7-[[3-(3-fluorophenyl)-1-azetidinyl]carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

7-[[(6-fluoro-1,2,3,4-tetrahydro-1(R)-naphthalenyl)amino]carbonyl]-3-phenyl-2-quinoxalinepentanoic acid,

(R)-5-(3-phenyl-7-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)quinoxalin-2-yl)pentanoic acid,

(S)-5-(3-(4-chlorophenyl)-7-((1-(3,4-difluorophenyl)ethyl)carbamoyl)quinoxalin-2-yl)pentanoic acid,

(R)-5-(3-(4-chlorophenyl)-7-((1-(3,5-difluorophenyl)ethyl)carbamoyl)quinoxalin-2-yl)pentanoic acid,

5-(3-(4-chlorophenyl)-7-(3-(4-chlorophenyl)azetidine-1-carbonyl)quinoxalin-2-yl)pentanoic acid,

5-(7-(((R)-5-fluoro-2,3-dihydro-1H-inden-1-yl)carbamoyl)-3-(4-fluorophenyl)quinoxalin-2-yl)-2-methylpentanoic acid,

(R)-5-(7-(chroman-4-ylcarbamoyl)-3-(4-fluorophenyl)quinoxalin-2-yl)pentanoic acid,

(S)-5-(3-(4-chlorophenyl)-7-(chroman-4-ylcarbamoyl)quinoxalin-2-yl)pentanoic acid,

(R)-5-(7-(chroman-4-ylcarbamoyl)-3-phenylquinoxalin-2-yl)pentanoic acid,

5-(3-(4-chlorophenyl)-7-(3-oxo-3,4-dihydro-2H-spiro[isoquinoline-1,4′-piperidin]-1′-ylcarbonyl)quinoxalin-2-yl)pentanoic acid, and

5-(3-(4-chlorophenyl)-7-(4-(2,6-dimethylphenyl)piperazine-1-carbonyl)quinoxalin-2-yl)pentanoic acid.

15. A pharmaceutical composition comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16. A method for treating asthma, congestion, allergic rhinitis or COPD comprising administering to a patient in need of such treatment of an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is phenyl, pyridyl, or thienyl; wherein R 2 is unsubstituted or substituted by 1 to 2 R 5 groups independently selected from the group consisting of fluoro, chloro, trifluoromethyl, C 1 -C 3 alkoxy, —CN and —OCF 3 .

18. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein

R 1 is —C(O)—N(R 6a )(R 6b )

I) R 6a is H and R 6b is

a) -Q-R AH , wherein R AH is phenyl,

and wherein R AH is unsubstituted or substituted with 1 R 8 moiety selected from the group consisting of fluoro and —CN;

b) -Q-R HC , wherein R HC is C 5 -C 6 cycloalkyl, wherein said C 5 -C 6 cycloalkyl is fused to a benzene ring;

and wherein R HC is unsubstituted or substituted with 1 to 2 R 12 moieties independently selected from the group consisting of halo and —CN;

II) or R 6a and R 6b together with the N atom to which they are attached form R 6H , wherein R 6H is pyrrolidinyl, piperidinyl, or piperazinyl;

wherein R 6H is substituted with —Z—R CY wherein

R CY is unsubstituted phenyl or phenyl substituted by 1 to 2 R 10 moieties selected from the group consisting of halo and —CN;

R 6H is optionally substituted by 1 to 2 R 9 moieties wherein each R 9 moiety is independently C 1 -C 3 alkyl, halo or —CN,

R 2 is unsubstituted phenyl; and

Q and Z are as set forth in claim 13 .

19. The compound of claim 18 or a pharmaceutically acceptable salt thereof, wherein R 6a and R 6b together with the N atom to which they are attached form R 6H , wherein R 6H is piperazinyl.

20. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of

(R)-4-((7-(4-(4-fluorophenyl)-2-methylpiperazine-1-carbonyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid,

(R)-4-((7-((1-(4-fluorophenyl)ethyl)carbamoyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid,

(R)-4-((7-((6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid,

4-((3-phenyl-7-(4-phenylpiperazine-1-carbonyl)quinoxalin-2-yl)amino)butanoic acid,

(R)-4-((7-((1-(4-cyanophenyl)ethyl)carbamoyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid,

4-((7-(4-(4-fluorophenyl)piperazine-1-carbonyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid,

(R)-4-((3-phenyl-7-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)quinoxalin-2-yl)amino)butanoic acid,

4-((7-(4-(4-fluorophenyl)piperidine-1-carbonyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid,

4-((7-(4-(4-chlorophenyl)piperidine-1-carbonyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid,

4-((7-(4-(4-chlorophenyl)piperazine-1-carbonyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid,

(R)-4-((3-phenyl-7-(3-phenylpyrrolidine-1-carbonyl)quinoxalin-2-yl)amino)butanoic acid, and

(R)-4-((7-(2-methyl-4-phenylpiperazine-1-carbonyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid.

21. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein the compound is (R)-4-((7-((6-fluoro-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid.

22. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein the compound is 4-((3-phenyl-7-(4-phenylpiperazine-1-carbonyl)quinoxalin-2-yl)amino)butanoic acid.

23. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein the compound is (R)-4-((7-(4-(4-fluorophenyl)-2-methylpiperazine-1-carbonyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid.

24. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein the compound is (R)-4-((7-((1-(4-cyanophenyl)ethyl)carbamoyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid.

25. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein the compound is 4-((7-(4-(4-fluorophenyl)piperazine-1-carbonyl)-3-phenylquinoxalin-2-yl)amino)butanoic acid.

26. The compound of claim 13 or a pharmaceutically acceptable salt thereof, wherein the compound is (R)-4-((3-phenyl-7-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)quinoxalin-2-yl)amino)butanoic acid.

27. The method of claim 16 , wherein the method is for treating asthma in a patient in need of such treatment.